Brief Enhanced Anxiety Sensitivity Treatment (Group)

Not Applicable

Completed

• Conditions: Anxiety; Anxiety Sensitivity
• Interventions: Behavioral: Control group Anxiety Sensitivity Treatment; Behavioral: Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)

• Registration Number: NCT05458362
• Lead Sponsor: Ohio University

Brief Summary

One-third of the U.S. population experience anxiety disorders in their lifetime and only 25% of them seek treatment, reporting logistics and cost of treatment among the primary barriers. A potential way to prevent and treat multiple anxiety disorders is to target the risk factors that contribute to their etiology. One such well-researched risk factor is anxiety sensitivity (AS), a fear of anxiety-related sensations. Given a need for affordable and accessible brief treatments, we and our colleagues have been iteratively developing Brief Enhanced Anxiety Sensitivity Treatment (BEAST), a one-session virtual treatment targeting AS. Older versions of BEAST include psychoeducation, interoceptive exposure (IE), and IE homework. Several studies showed that the previous versions of BEAST reduced AS and, through the reductions in AS, they also reduced anxiety. However, the effect sizes for the decrease in anxiety were modest. Efficacy and personalization may be improved using Ecological Momentary Intervention (EMI). EMI delivers brief interventions remotely in real-time and in natural settings. The goal of the current study is to test the efficacy of adding EMI to BEAST. Participants will be randomly assigned to EMI and control (no EMI) conditions. All participants will receive a virtual 1.5-hour-long intervention group session facilitated by a therapist. The EMI group will receive individualized intervention messages helping them to use new skills for two weeks after the session. After the two-week EMI period, all participants will complete post-treatment measures of AS and anxiety. A month later, they will complete a follow-up assessing AS and anxiety. The efficacy of the EMI component in reducing AS and anxiety will be tested using multilevel modeling. Improving the efficacy of BEAST, while keeping it brief, affordable, and accessible online, is an important step towards making it a treatment that may be used on a large scale.

Detailed Description

There is a high need for prevention and treatment of anxiety disorders and for more accessible and affordable treatments. Targeting a risk factor for development and maintenance of multiple anxiety disorders may be an efficient way to prevent and treat anxiety. Anxiety sensitivity (AS)-the fear of anxiety sensations because of the belief that these sensations may lead to catastrophic outcomes-is a potent prevention and treatment target because it predicts development and maintenance of anxiety over time. Anxiety Sensitivity Amelioration Training (ASAT) is an ultra-brief, affordable treatment delivered virtually that targets AS. ASAT is a potent prevention and treatment protocol that reduces anxiety by reducing AS. However, the effect sizes were modest.

Adding Ecological Momentary Intervention (EMI) to the treatment could motivate the participants to apply skills they learned in treatment in a variety of real-life situations and to practice homework exercises. EMI delivers the intervention remotely in real-time and in natural settings, providing better learning through deeper processing. EMI alone is an effective treatment for anxiety and has been an efficacious enhancement to a 6-session treatment for generalized anxiety disorder. However, adding EMI to a 6-session panic disorder treatment did not improve the efficacy of the intervention. Because EMI can reduce anxiety as a stand-alone treatment and due to the inconclusive results about the efficacy of EMI as an added component, it is important to test the effect of adding EMI to the ASAT. We called the treatment including EMI the Brief Enhanced Anxiety Sensitivity Treatment (BEAST).

The goal of this study is to compare the efficacy of the BEAST with and without the EMI component. Interventions will be delivered to the adult community members and students in Athens, Ohio. Based on the power analysis, 75 adult participants will be recruited using email and online advertising. Based on methods used in the prior studies and the current design, inclusion criteria are elevated AS symptoms, access to a smartphone with internet connection. Exclusion criteria are heart disease, respiratory disorders, renal disease, seizure disorder, uncontrolled hypertension or migraines, current substance use disorder (severe), uncontrolled manic or psychotic symptoms, and suicidal ideation that requires hospitalization. All participants will receive a one-hour manualized group intervention educating about anxiety as an alarm system, the benign nature of anxiety sensations, myth-busting, and modifying biases about feared stimuli. The session will also include therapist-guided interoceptive exposure. Participants will be asked to do the exposure at home at least once a day for two weeks. For two weeks after the session, four times a day, the EMI group will receive prompts via the HIPAA-compliant EMI application (metricwire.com). The prompts will ask them about their current anxiety level. If they endorse elevated anxiety, they will be provided with a brief message reminding them about the coping skills covered during the session. They will also receive daily prompts to do exposures and enter the results in the app. The control group will not receive the EMI prompts and will be offered to complete EMI four weeks after the treatment. The intervention will be delivered by graduate students in a clinical Ph.D. program using Microsoft Teams, in groups of 4-6 participants.

AS and anxiety will be assessed using online questionnaires at baseline, at week two and week six after the delivery of the intervention session. Brief interview will be administered at baseline to assess the pathology listed in the exclusion criteria. Multilevel modeling will be used compare AS and anxiety between the groups at both follow-ups controlling for the baseline AS and anxiety. BEAST is an affordable intervention that can be used for prevention and treatment of anxiety and can be administered virtually. This is the first study testing the efficacy an added EMI component to a one-session-long anxiety intervention.

Study Timeline

• Study Start: 2022-02-09
• Study First Submitted: 2022-05-06
• Primary Completion: 2022-07-04
• Study Completion: 2022-07-04
• Study First Submitted QC: 2022-07-10
• Study First Posted: 2022-07-14
• Status Verified: 2022-12
• Last Update Submitted: 2022-12-08
• Last Update Posted: 2022-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 73

Inclusion Criteria

• elevated anxiety sensitivity symptoms (i.e., ASI-3 scores greater than or equal to 17),
• have access to a device smartphone with internet connection.

Exclusion Criteria

• cardiovascular disease or stroke
• respiratory disorders (asthma, COPD, other),
• renal disease,
• epilepsy or other seizure disorder,
• and uncontrolled hypertension or migraines.
• current substance use disorder (severe),
• uncontrolled manic symptoms,
• uncontrolled psychotic symptoms,
• suicidal ideation that requires hospitalization,
• if the participants endorse that English is not their first language in the screening questionnaire and demonstrate significant impairment in understanding the interviewer, they will be considered not proficient in English and will be excluded from the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Control group Anxiety Sensitivity Treatment	The control group will not receive EMI prompts and will be offered to complete EMI after the follow-up assessment.
EMI group	Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)	For two weeks after the intervention session, participants will report on their anxiety level four times per day. When participants endorse elevated anxiety, they will receive a message relevant to their most stressful symptom at the moment reminding them of the topics covered in the intervention session. As the efficacy of the EMI component is being tested, only the EMI group will receive EMI.

Primary Outcome Measures

Name	Time	Method
Change in Anxiety Sensitivity Inventory-3 (ASI-3; Taylor et al., 2007)	Screening, baseline, post-treatment including EMI (2 weeks after the session), 1 month follow-up.	The ASI-3 is an 18-item self-report questionnaire of anxiety sensitivity measured on a 5-point Likert-like scale ranging from 0 (very little) to 4 (very much).
Change in PROMIS Anxiety scale - 8a	Baseline, post-treatment including EMI (2 weeks after the session), 1 month follow-up.	The PROMIS Anxiety scale measures anxiety broadly, including items to assess fear, anxious misery, hyperarousal, and somatic symptoms. Items are on a 5-point scale from 1 (Never) to 5 (Always).

Secondary Outcome Measures

Name	Time	Method
Daily change - PROMIS Anxiety Short Form 8a Modified (all participants)	2 weeks of EMI - 1 time a day	The PROMIS Anxiety Short Form will be modified to assess anxiety symptoms the participant has experienced yesterday as opposed to 7 past days. This measure will be added to the first EMI prompt of the day. This will allow us to measure the change in the participants anxiety symptoms daily.
Change multiple times a day - EMI anxiety questions (EMI group)	2 weeks of EMI - 4 times a day	On every EMI measurement occasion, participants will be asked to report their level of anxiety using the question "How anxious are you?" on a scale ranging from 0 to 100. If they endorse elevated anxiety of 30 or above (Newman et al., 2014), they will be sent another question: What stressful symptoms are you experiencing? (a) Body sensations, (b) Mind and concentration, (c) Concerned about being judged for your anxiety symptoms. Next, they will be asked to choose a specific symptom from the dimension they have picked. Based on this symptom, they will be shown a message offering a CBT strategy to cope with the symptom and the distress effectively.; We will be sending the prompt 80% of the time when an elevated symptom level is reported (30-100 on a sliding scale) and provide intervention in 10% of cases when a low level of the symptom is reported (0-29 on a sliding scale).
Daily change - Short Scale Anxiety Sensitivity Index (all participants)	2 weeks of EMI - 1 time a day	SSASI is a short version of the ASI-3 (Taylor et al., 2007). It is a 5-item questionnaire measuring AS on a 5-item Likert scale from 0 (very little) to 4 (very much). The SSASI has items corresponding to all three dimensions of AS: Physical concerns, cognitive concerns, and social concerns. This measure will be added to the first EMI prompt of the day. This will allow us to measure the change in the participants AS symptoms daily. The SSASI will be modified to assess symptoms during the past 24 hours.

Trial Locations

Locations (1)

Ohio University; 🇺🇸 Athens, Ohio, United States